-transparent.png){kind=logo}
Alizapride is a new antidopaminergic-related benzamide with specific antiemetic properties. Pharmacokinetics at a high repetitive dose (16 mg/kg) shows a biexponential plasma decay with T1/2 alpha of 8.33 +/- 2.47 min and T1/2 beta 2.8 +/- 0.7 hr. Large Vdss and high total body clearance are apparent. We demonstrate an increase in drug exposure during the first 6 hr after CDDP infusion by shortening the interval between injections. We conclude that the rate of infusion of alizapride could be important in the efficacy of the drug.
Related Publications
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
November 1985,
Cancer treatment reports,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
January 1987,
Cancer investigation,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
October 2003,
Anti-cancer drugs,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
January 1985,
Clinical pharmacology and therapeutics,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
September 1992,
Lancet (London, England),
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
January 1988,
Oncology,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
January 1985,
Current medical research and opinion,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
June 1988,
Clinical pharmacy,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
September 1990,
Cancer,
P Canal, and
H Roche, and
M Pasquier, and
R Bugat, and
D Berg, and
G Soula, and
M Carton
January 1993,
European urology,
